Pharmacokinetics and Food Interactions
Captopril has a good absorption rate in the gastrointestinal tract. However, its pharmacokinetics has a vulnerable point: a pronounced dependence on gastric contents. If a patient takes the tablet with food, the bioavailability of the active substance drops drastically, with absorption decreasing to 30–55%. This means that a significant portion of the dose fails to enter the systemic circulation, leading to a lack of the expected antihypertensive response. For this reason, physicians strictly regulate the timing of administration relative to meals.
Regarding time parameters, the drug is classified as a short-acting agent. After oral administration, the onset of the therapeutic effect is recorded within 30–60 minutes, making it convenient for rapid blood pressure control. The flip side is the duration of action, which is limited to 4–8 hours. Due to this short therapeutic window, frequent multiple daily doses are required to maintain a stable 24-hour blood pressure profile.
Pharmacodynamics and Vascular Effects
The pharmacodynamic profile of the drug is based on its ability to induce systemic vasodilation. First, there is marked dilation of peripheral arteries, which directly leads to a decrease in total peripheral resistance (TPR), a key factor determining blood pressure levels. Concurrently, some venous dilation occurs, increasing venous capacitance.
This complex effect on the arterial and venous beds has a powerful positive impact on the heart. Venodilation decreases venous return to the right atrium, clinically reducing preload. Simultaneously, the drop in TPR facilitates blood ejection from the left ventricle, thereby decreasing myocardial afterload.
In addition to systemic effects, the drug selectively modulates regional blood flow. It has a proven positive effect on microcirculation: it reliably improves circulation in the pulmonary circulation and normalizes renal hemodynamics.
Indications
Based on the hemodynamic effects described, there are two main clinical applications for the drug:
- Hypertension. The drug successfully lowers blood pressure and is particularly effective in patients with high-renin forms of hypertension. In such cases, the pathogenesis of the disease is closely linked to hyperactivation of the renin system, and direct ACE inhibition interrupts this pathological cascade.
- Heart Failure (HF). In heart failure, the myocardium struggles to pump blood effectively. The drug's ability to reduce preload and afterload significantly unloads the weakened heart muscle, improves cardiac pump function, and optimizes pulmonary circulation.
Adverse Effects
Interference with complex biochemical processes inevitably entails a number of adverse effects. For clarity, they are classified by mechanism:
- Bradykinin-mediated. Accumulation of bradykinin in tissues irritates airway receptors, causing a debilitating dry cough. In more severe cases, excess bradykinin provokes angioedema.
- Aldosterone deficiency-mediated. Decreased aldosterone levels predictably inhibit potassium excretion by the kidneys, leading to ion retention and the development of hyperkalemia.
- Other adverse reactions. Renal involvement may manifest as proteinuria (loss of protein in the urine). The nervous system may react with headaches and dizziness. Allergic manifestations such as skin rashes are also possible.